Author: admin

“Influenza A Infections – Market Insight, Epidemiology And Market Forecast – 2032”

DelveInsight’s report titled “Influenza A Infections – Market Insight, Epidemiology And Market Forecast – 2032” provides a comprehensive analysis of the historical and projected market size for Influenza A infections from 2019 to 2032. The report examines various epidemiological segments and forecasts, explores market trends for Influenza A infections, assesses the competitive landscape, evaluates current and emerging therapeutic approaches, and identifies unmet needs in the treatment of Influenza A infections.

According to the report, the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, reached USD 3.6 billion in 2021. The market is expanding steadily due to rising vaccination rates, innovative antiviral therapies, and government-backed initiatives aimed at combating seasonal influenza. Projections indicate sustained growth through 2032, with the U.S. dominating the market among the 7MM countries.

Download the influenza A market report to understand which factors are driving the influenza A therapeutic market @ Influenza A Market Trends.

The epidemiological data presented in the report highlights the significant impact of Influenza A across the 7MM, with patterns emerging in prevalence, strain distribution, and vaccination rates. One of the most notable trends is the increasing prevalence of Influenza A infections. In the US alone, over 176 million individuals were vaccinated against Influenza A in 2021. More recently, Influenza A strains, primarily A/H3N2 and A/H1N1 which tend to be more severe due to their higher transmissibility and virulence, are attributed to most of the recent cases, especially in 2024-2025. This underscores the widespread nature of the virus, especially among seasonal strains.

Discover evolving trends in influenza A patient pool forecasts @ Influenza A Epidemiology Analysis.

The Influenza A treatment landscape comprises established antiviral medications, emerging therapies, and preventive strategies that aim to mitigate the disease’s impact. Current therapeutics focus on reducing the severity and duration of symptoms, preventing complications, and addressing challenges posed by evolving viral strains. Recommended antiviral drugs for treatment include TAMIFLU (Roche), RELENZA (GSK), RAPIVAB (BioCryst Pharmaceuticals), XOFLUZA (Genentech/Roche/Shionogi & Co.), and FLUZONE QUADRIVALENT (Sanofi), among others. These antiviral medications shorten the duration of symptoms and reduce the risk of severe complications in high-risk populations.

DelveInsight’s analysis indicates that the current developmental pipeline for influenza treatments is robust. Notable candidates include CD388 (Cidara Therapeutics), SAB-176 (SAB Biotherapeutics), and VIR-2482 (Vir Biotechnology), among others. These therapies represent significant advancements in addressing unmet needs in Influenza A prevention and treatment, particularly for high-risk populations and those facing vaccine limitations.

Recent developments in the Influenza A landscape across the 7MM highlight significant advancements in vaccine technology, antiviral therapies, and emerging drug candidates, reshaping the prevention and treatment of Influenza A and addressing both seasonal epidemics and pandemic preparedness. An important advancement in the influenza landscape is the shift towards mRNA-based vaccine technologies. Following the success of mRNA vaccines for COVID-19, pharmaceutical companies are strategically repurposing this technology for influenza vaccines.

Another significant change is the transition from egg-based production methods to cell culture-based methods. This shift offers enhanced flexibility, scalability, and safety in production. Cell culture-based methods help meet vaccine demands more sustainably and ensure timely supply during both seasonal epidemics and potential global pandemics.

The quest for a universal influenza vaccine, which could provide broad and durable protection against all influenza virus strains, continues to be a priority. Current strategies focus on targeting highly conserved regions of hemagglutinin (HA), neuraminidase (NA), the M2 extracellular domain (M2e), and internal proteins of the influenza virus.

Innovation in vaccine delivery systems is also progressing rapidly. In January 2025, Micron Biomedical received a $2 million award from the U.S. Department of Health and Human Services to develop needle-free versions of broadly protecting influenza vaccines in collaboration with Zipcode Bio. In September 2024, the FDA also approved FluMist for the prevention of influenza caused by influenza virus subtypes A and B in individuals 2 through 49 years of age.

Unlock which influenza A drug is expected to capture the largest market share in 7MM by 2034. Visit the Influenza A Insights.

Additionally, the FDA has recommended updated formulations for the 2025–2026 influenza vaccine, which include new strains of Influenza A/H3N2 viruses to improve efficacy against circulating variants.

Looking ahead, the Influenza A infections market looks promising with advancements in treatment and prevention strategies aimed at overcoming resistance challenges and improving outcomes for high-risk populations. Strategic partnerships among leading pharmaceutical companies will accelerate research and development efforts, while government-backed initiatives will continue to enhance vaccination rates.

Table of Contents

Related Reports

Influenza A Infections Pipeline Insight

Influenza A Infections Pipeline Insight provides comprehensive insights about the Influenza A Infections pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Influenza A Infections manufacturers, including Roche, GSK, BioCryst Pharmaceuticals, Genentech, Shionogi & Co., Sanofi, Cidara Therapeutics, SAb Biotherapeutics, Vir Biotechnology, and Micron Biomedical, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Influenza A Infections Market to Witness Robust Growth Through 2032, Driven by mRNA Vaccines, Antiviral Innovation, and Government Initiatives | DelveInsight

“Plasmacytoma – Market Insight, Epidemiology And Market Forecast – 2032”

DelveInsight’s “Plasmacytoma – Market Insight, Epidemiology And Market Forecast – 2032” report provides a detailed analysis of Plasmacytoma market trends, epidemiological patterns, and therapeutic development across the 7MM. The market for Plasmacytoma, a rare plasma cell disorder, is expected to experience robust growth through 2032, primarily driven by factors such as the rising prevalence of gene mutations, increased exposure to toxins and chemicals, and the escalating utilization of immunomodulatory drugs for treatment. Additionally, the market is benefiting from advancements in stem cell transplants and the emerging popularity of radiation therapies like brachytherapy. Additionally, the United States will continue to dominate the market share, followed by the EU5 countries and Japan.

Download the Plasmacytoma market report to understand which factors are driving the Plasmacytoma therapeutic market @ Plasmacytoma Market Trends.

The epidemiological landscape of the Plasmacytoma patient pool reveals distinctive patterns across the 7MM (United States, EU5, and Japan). The United States has the largest patient pool among the 7MM. The Plasmacytoma market size in Japan shows a proportionally smaller patient population. Across all regions, the disease primarily affects adults over 40 years old, with incidence increasing with age. Additionally, incidence rates were higher among men than women for both types of plasmacytoma (SBP and EMP).

Discover evolving trends in Plasmacytoma patient pool forecasts @ Plasmacytoma Epidemiology Analysis.

The DelveInsight report also examines the current and emerging Plasmacytoma treatment landscape. The current treatment market encompasses several therapeutic approaches. Monoclonal antibodies like DARZALEX (Janssen Biotech) have revolutionized treatment protocols. Additionally, the treatment landscape also includes proteasome inhibitors – VELCADE (Millennium/Takeda and Janssen Pharmaceutical Companies), KYPROLIS (Onyx Pharmaceuticals), and NINLARO (Takeda), and immunomodulatory drugs – REVLIMID (Bristol-Myers Squibb), THALOMID (BMS), POMALYST (BMY), offering multiple therapeutic options for clinicians. Though these drugs are approved for related plasma cell disorders, particularly multiple myeloma, some of them are currently being evaluated specifically for Plasmacytoma treatment.

The competitive landscape of the Plasmacytoma market features several key players. Bristol-Myers Squibb (NASDAQ: BMY) and Janssen/Johnson & Johnson (NASDAQ: JNJ) hold significant market shares and generate substantial revenue. Other major contributors to the Plasmacytoma therapeutics market include Takeda Pharmaceuticals (NASDAQ: TAK), Sanofi (NASDAQ: SAN), GSK, and Pfizer (NASDAQ: PFE), each developing innovative therapies to address unmet needs in this space. The Plasmacytoma treatment market is characterized by active research and development, with companies investing heavily in novel therapeutic approaches to improve patient outcomes.

Know which Plasmacytoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Plasmacytoma Insights.

Despite the positive growth trajectory, the Plasmacytoma drug market faces several challenges, including the rarity of the disease, high treatment cost for advanced therapies, and the lack of durable therapies, resulting in more than 50% of patients with Plasmacytoma progressing to multiple myeloma.

However, substantial plasmacytoma market drivers offset these challenges, including increasing disease awareness, improved diagnostic capabilities, and growing healthcare expenditure in key markets. The Plasmacytoma pipeline is robust, featuring next-generation CELMoDs (designed to replace REVLIMID after patent expiry), novel bispecific antibodies, and personalized treatment approaches, all promising to expand therapeutic options for Plasmacytoma patients.

Furthermore, strategic partnerships and collaborations among pharmaceutical companies are increasingly shaping the Plasmacytoma treatment landscape, with joint development initiatives accelerating the progression of promising therapies through clinical trials. These alliances are particularly crucial for complex therapies like CAR-T, where specialized expertise and manufacturing capabilities can significantly impact market success. Additionally, emerging technological innovations, including artificial intelligence applications in drug discovery and digital health solutions for patient monitoring, represent exciting frontiers in the Plasmacytoma market, potentially revolutionizing treatment paradigms and improving outcomes for the Plasmacytoma patient pool across the globe.

Table of Contents

Related Reports

Plasmacytoma Pipeline Insight

Plasmacytoma Pipeline Insight provides comprehensive insights about the Plasmacytoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Plasmacytoma manufacturers, including Bristol Myers Squibb, Janssen/Johnson & Johnson, GSK, Pfizer, Celgene, and Takeda, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Plasmacytoma Market Set for Robust Growth Through 2032, Driven by Advances in CAR-T, Monoclonal Antibodies, and Immunomodulators | DelveInsight

“RL-007 Market Size, Forecast, and Emerging Insight ? 2032”

According to comprehensive market insights from DelveInsight’s report, “RL-007 Market Size, Forecast, and Emerging Insight − 2032“, RL-007 represents a substantial opportunity in the 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. There are more than 3 million prevalent cases of CIAS in these regions. The total CIAS market size in the 7MM was valued at approximately USD 1 billion in 2023, and this is projected to increase significantly over the next 10 years.

Developed by ATAI Life Sciences through its subsidiary Recognify Life Sciences, RL-007 operates through a unique mechanism that sets it apart from conventional schizophrenia treatments. This orally available compound acts as a GABA/nicotinic modulator, altering the excitatory/inhibitory balance in the brain to produce pro-cognitive effects. The RL-007 MOA involves modulation of cholinergic, glutamatergic, and GABA-B receptors, which has shown remarkable efficacy in addressing cognitive deficits without the side effects commonly associated with traditional antipsychotics.

Download the RL-007 market report to understand the RL-007 market potential @ RL-007 Market Trends.

Cognitive impairment affects approximately 80% of schizophrenia patients, causing significant disability and affecting occupational, social, and economic functioning. Despite this high prevalence, there are currently no FDA-approved medications specifically targeting CIAS, highlighting the urgent need for innovative therapies like RL-007.

RL-007 clinical development has progressed significantly, having been evaluated in more than ten clinical studies, including Phase I and Phase II trials involving over 500 participants. The completed Phase IIa proof-of-mechanism study showed that RL-007 was well-tolerated and exhibited a clinically meaningful pro-cognitive profile, particularly improving verbal learning, memory, and processing speed.

Following the positive results of earlier phases, ATAI Life Sciences initiated a Phase IIb proof-of-concept trial, designed as a randomized, placebo-controlled, double-blind, three-arm study assessing two doses of RL-007 against a placebo in 234 patients aged 18–55 with stable schizophrenia. The trial uses the MATRICS Consensus Cognitive Battery (MCCB) as the primary endpoint, which has been endorsed by the FDA as an approvable endpoint for CIAS therapies. This robust approach to efficacy assessment enhances the potential for RL-007’s FDA approval upon successful completion of the required clinical program. As of April 2025, the trial is ongoing, with no interim results released.

Download the RL-007 market report to understand how RL-007 helps manage cognitive symptoms of schizophrenia @ RL-007 Mechanism of Action.

Additionally, Iclepertin (BI 425809), a GlyT1 inhibitor being developed by Boehringer Ingelheim, is currently in Phase III clinical trials and has also demonstrated pro-cognitive effects in earlier studies. If successful, Iclepertin could become the first approved pharmacotherapy for CIAS. However, it remains investigational and has not yet reached the market.

With no approved therapies for CIAS, the market has long remained untapped, leaving a significant unmet need for patients with schizophrenia. RL-007, with its promising safety profile and pro-cognitive efficacy, stands out as a potential breakthrough. As this and other emerging therapies advance through clinical development, analysts anticipate a transformative shift in the market. According to DelveInsight’s forecast, the approval of these novel treatments is expected to drive CIAS market growth at a CAGR of 8.9% from 2024 to 2034.

Gain more insights into how RL-007 is progressing in clinical trials and how it compares to competing therapies in the cognitive impairment space @ RL-007 Clinical Trials.

In conclusion, RL-007 has shown consistent pro-cognitive effects across preclinical and clinical studies, with improvements in verbal learning and memory that suggest its potential benefits may extend beyond CIAS to other cognitive disorders. RL-007’s unique pharmacology, along with its rapid onset of action and excellent tolerability profile, sets it apart from other pipeline options.

As RL-007 progresses through late-stage clinical development, it represents a significant advancement in schizophrenia treatment, potentially offering one of the first approved therapies specifically aimed at the cognitive symptoms that greatly affect the quality of life and functional outcomes for schizophrenia patients.

Table of Contents

Related Reports

Schizophrenia Pipeline Insight

Schizophrenia Pipeline Insight provides comprehensive insights about the Schizophrenia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Schizophrenia manufacturers, including Sunovion Pharmaceuticals, Denovo BioPharma, Cyclerion Therapeutics, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, and Sirtsei Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: RL-007 Poised to Transform CIAS Market as First Targeted Therapy for Cognitive Deficits in Schizophrenia | DelveInsight